Your Good Partner in Biology Research

Mouse Fibroblast growth factor 23(FGF23) ELISA kit

  • 中文名称:
    小鼠成纤维细胞生长因子23(FGF23)酶联免疫试剂盒
  • 货号:
    CSB-EL008629MO
  • 规格:
    96T/48T
  • 价格:
    ¥3600/¥2500
  • 其他:

产品详情

  • 产品描述:

    This Mouse FGF23 ELISA Kit was designed for the quantitative measurement of Mouse FGF23 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 23.44 pg/mL-1500 pg/mL and the sensitivity is 5.86 pg/mL.

  • 别名:
    Fgf23Fibroblast growth factor 23 ELISA kit; FGF-23 ELISA kit
  • 缩写:
  • Uniprot No.:
  • 种属:
    Mus musculus (Mouse)
  • 样本类型:
    serum, plasma, tissue homogenates
  • 检测范围:
    23.44 pg/mL-1500 pg/mL
  • 灵敏度:
    5.86 pg/mL
  • 反应时间:
    1-5h
  • 样本体积:
    50-100ul
  • 检测波长:
    450 nm
  • 研究领域:
    Signal Transduction
  • 测定原理:
    quantitative
  • 测定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 线性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of mouse FGF23 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
      Sample Serum(n=4)
    1:1 Average % 102
    Range % 98-107
    1:2 Average % 85
    Range % 80-90
    1:4 Average % 91
    Range % 85-95
    1:8 Average % 94
    Range % 90-98
  • 回收率:
    The recovery of mouse FGF23 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range
    Serum (n=5) 90 85-94
    EDTA plasma (n=4) 97 93-101
  • 标准曲线:
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/ml OD1 OD2 Average Corrected
    1500 2.614 2.468 2.541 2.386
    750 2.103 2.095 2.099 1.944
    375 1.587 1.513 1.550 1.395
    187.5 1.002 1.074 1.038 0.883
    93.75 0.564 0.554 0.559 0.404
    46.88 0.356 0.382 0.369 0.214
    23.44 0.245 0.239 0.242 0.087
    0 0.159 0.151 0.155  
  • 数据处理:
  • 货期:
    3-5 working days

产品评价

靶点详情

  • 功能:
    Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblasts differentiation and matrix mineralization. Upregulates EGR1 expression in the presence of KL.
  • 基因功能参考文献:
    1. Increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in acute kidney injury. PMID: 29395333
    2. our data highlight a role of FGF23/FGFR4 signaling in the regulation of cardiac remodeling and function, and indicate that pharmacological interference with cardiac FGF23/FGFR4 signaling might protect from CKD- and age-related LVH. PMID: 28512310
    3. the main physiological function of Klotho for mineral homeostasis in vivo is its role as co-receptor mediating Fgf23 action. PMID: 28600880
    4. our study provided histological evidences that sclerostin tends to be secreted in osteocytes of remodeled mature bone, while FGF23 would be differently synthesized in osteoblasts and osteocytes according to the developmental stages PMID: 28794403
    5. these results indicate that Nf1 deficiency in osteocytes dramatically increases FGF23 production and causes a mineralization defect (ie, hyperosteoidosis) via the alteration of calcium-phosphorus metabolism. PMID: 28425622
    6. FGF23 promotes myocardial fibrosis and exacerbates diastolic dysfunction induced by myocardial infarction or ischemia/reperfusion , which is associated with the upregulation of active beta-catenin and TGF-beta PMID: 27579618
    7. deleting FGF23 within early osteoblasts and osteocytes demonstrated that both cell types contribute to baseline circulating FGF23 concentrations, and that targeting osteoblasts/osteocytes for FGF23 production can modify systemic responses to changes in serum phosphate concentrations and rescue the Hyp genetic syndrome PMID: 26792657
    8. Thus, monotherapy with 1,25D improves growth, skeletal microarchitecture, and bone strength in the absence of phosphate supplementation despite enhancing FGF23 expression, demonstrating that 1,25D has direct beneficial effects on the skeleton in XLH, independent of its role in phosphate homeostasis PMID: 26751835
    9. Zinc13407541 also inhibited FGF-23 signaling in isolated renal tubules ex vivo and partially reversed the hypophosphatemic effects of excess FGF-23 in a mouse model. These chemical probes provide a platform to develop lead compounds to treat disorders caused by excess FGF-23. PMID: 27879395
    10. FGF23 may be an important modulator of PTH signaling in bone and kidney. PMID: 27498418
    11. EPO dependent regulation pathway of FGF23 gene expression PMID: 29073196
    12. can directly stimulate hepatic secretion of inflammatory cytokines PMID: 27457912
    13. Klotho in bone is crucial for inducing FGF23 production upon renal failure PMID: 28183805
    14. dietary iron content and chronic kidney disease affected FGF23 production and metabolism PMID: 27733366
    15. Dmp1 mutation creates a lower set point for extracellular phosphate and maintains it through the regulation of Fgf23 cleavage and expression PMID: 28005411
    16. Although FGF23 is present in the fetal circulation at levels that may equal adult values, and there is robust expression of FGF23 target genes in placenta and fetal kidneys, FGF23 itself is not an important regulator of fetal phosphorous metabolism. PMID: 27929669
    17. Annexin A7 deficiency upregulates FGF23 plasma levels, an effect paralleled by increased corticosterone plasma levels, as well as decreased 1,25(OH)2 D3 and PTH plasma levels. PMID: 27871077
    18. FGF23 regulates osteopontin secretion indirectly by suppressing alkaline phosphatase transcription and phosphate production in osteoblastic cells, acting through FGF receptor-3 in a Klotho-independent manner PMID: 26235988
    19. AHSG is produced in bone, mainly in osteocytes and also show for the first time that its production is modulated by FGF23. PMID: 26476373
    20. Data suggest that Fgf23 level in serum is up-regulated by three forms of exercise (acute exercise, exhaustive exercise, and chronic exercise); however, only chronic exercise up-regulates FGF23 mRNA and protein expression in skeletal muscle. PMID: 27085781
    21. Data suggest that signal transduction via Fgf23/Fgfr1 and calcitriol/calcitriol receptor have opposite roles in innate immunity; Fgf23 suppresses arginase-1 expression in macrophages; calcitriol stimulates arginase-1 expression in macrophages. PMID: 26762170
    22. results link CYP24 activity to the pathophysiology of FGF23-dependent renal phosphate wasting states and implicate pharmacologic CYP24 inhibition as a therapeutic adjunct for their treatment. PMID: 26784541
    23. Although the molecular link between the cardiac lesion and circulating Fgf23 concentrations remains to be identified, our study has uncovered a novel heart-bone-kidney axis PMID: 25858796
    24. Akt/PKB/SGK-sensitive GSK3 inhibition participates in the regulation of FGF23 release, 1,25(OH)2D3 formation, and thus mineral metabolism, by controlling the activity of the sympathetic nervous system. PMID: 26527066
    25. our data demonstrate that the effect of FGF23 on Pi homeostasis is mediated, at least in part, by activation of egr-1. PMID: 26588476
    26. Activation of FGFR1 is essential for the high levels of FGF23 in acute and chronic experimental uremia. PMID: 26311115
    27. findings revealed that FGF23 neutralization effectively improves bone quality and osseointegration of titanium implants in CKD mice, suggesting FGF23 as a key factor of CKD related bone diseases. PMID: 25665715
    28. the FGF23 proximal promoter harbors cis elements that drive responsiveness to 1,25D and calcium, agents that induce FGF23 to curtail the pathologic consequences of their excess. PMID: 26148725
    29. ctivation of autocrine/paracrine FGF pathways is involved in the pathogenesis of Hyp through FGFR1-dependent regulation of FGF23 by both transcriptional and post-transcriptional mechanisms. PMID: 25089825
    30. Normalization of serum FGF23 levels by did not abrogate the aggravated cardiac hypertrophy observed in Klotho-deficient chronic kidney disease. PMID: 25475745
    31. Fgf23-deficient mice are profoundly deaf. They have moderate hearing loss above 20 kHz, consistent with mixed conductive and sensorineural pathology of both middle and inner ear origin. these mice demonstrate dysplastic bulla and ossicles. PMID: 25243481
    32. Increased levels of circulating FGF23 in pathological conditions such as Hyp mice exerts direct effects on the placenta and affects fetal vitamin D metabolism. PMID: 24470103
    33. The polycystic kidney produces FGF23 but is resistant to its action. PMID: 24402093
    34. Fgf23- and Klotho-deficient mice show renal Na+ wasting and are hypovolemic. PMID: 24797667
    35. The stabilized Fgf23-autosomal dominant hypophosphatemic rickets allele reversed the Galnt3-null phenotype and normalized total Fgf23, serum phosphorus, and bone Fgf23 mRNA. PMID: 25051439
    36. High levels of FGF23 contribute to cardiovascular dysfunction. PMID: 25053401
    37. phosphate levels contribute in part to the high OPN levels in Fgf23(-/-) mice PMID: 24038141
    38. Circulating FGF23 level is increased in early chronic kidney disease (CKD) and is expressed in the vascular media of sham-operated mice; its expression is decreased in early CKD. PMID: 23884339
    39. disturbed iron and oxygen metabolism in neonatal life may have important effects on skeletal function and structure through FGF23 activity on phosphate regulation. PMID: 23873717
    40. FGF-23 is unlikely to have major effects on cardiovascular structure and function. PMID: 24525546
    41. The presence of Klotho-independent FGF23 effects in a Klotho-expressing target organ represents a paradigm shift in the conceptualization of FGF23 endocrine action PMID: 24348262
    42. Failed to find support for FGF23-mediated catabolism of vitamin D metabolites in chronic kidney disease assessed by 24,25(OH)(2)D levels. PMID: 22739976
    43. FGF23 directly affects the differentiation of bone marrow stromal cells PMID: 24068282
    44. P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development PMID: 24487286
    45. Data (including data from mutant/transgenic mice) suggest that FGF23 is not an important regulator of fetal phosphorous metabolism; active delivery of phosphorus across the placenta does not require FGF23. PMID: 24601885
    46. a novel role for FGF-23 in erythrocyte production and differentiation and suggest that elevated FGF-23 levels contribute to the pathogenesis of anemia PMID: 24509850
    47. observed a 3- to 10-fold increase in CYP27B1 mRNA abundance in the lung, spleen, aorta and testis of FGF-23 null/1alpha-Luc mice PMID: 24019880
    48. FGF23, not alphaKlotho, is a calcium-conserving hormone in the kidney. PMID: 24434184
    49. regulation of skeletal Fgf23 expression by sympathetic activity is dependent on the circadian clock system and may shed light on new regulatory networks of FGF23 PMID: 24302726
    50. High FGF23 variability in dialysis patients is mainly associated with lower baseline serum phosphorus. PMID: 23635517

    显示更多

    收起更多

  • 亚细胞定位:
    Secreted.
  • 蛋白家族:
    Heparin-binding growth factors family
  • 组织特异性:
    Mainly expressed in the brain and thymus at low levels. In brain; preferentially expressed in the ventrolateral thalamic nucleus.
  • 数据库链接: